The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; none of the 36 sources its claims cite is checked for support yet.
Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control
Open accessAbstract
IMPORTANCE: In older adults with multiple serious comorbidities and functional limitations, the harms of intensive glycemic control likely exceed the benefits. OBJECTIVES: To examine glycemic control levels among older adults with diabetes mellitus by health status and to estimate the prevalence of potential overtreatment of diabetes. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis of the data on 1288 older adults (≥65 years) with diabetes from the National Health and Nutrition Examination Survey (NHANES) from 2001 through 2010 who had a hemoglobin A1c (HbA1c) measurement. All analyses incorporated complex survey design to produce nationally representative estimates. EXPOSURES: Health status categories: very complex/poor, based on difficulty with 2 or more activities of daily living or dialysis dependence; complex/intermediate, based on difficulty with 2 or more instrumental activities of daily living or presence of 3 or more chronic conditions; and relatively healthy if none of these were present. MAIN OUTCOMES AND MEASURES: Tight glycemic control (HbA1c level, <7%) and use of diabetes medications likely to result in hypoglycemia (insulin or sulfonylureas). RESULTS: Of 1288 older adults with diabetes, 50.7% (95% CI, 46.6%-54.8%), representing 3.1 million (95% CI, 2.7-3.5), were relatively healthy, 28.1% (95% CI, 24.8%-31.5%), representing 1.7 million (95% CI, 1.4-2.0), had complex/intermediate health, and 21.2% (95% CI, 18.3%-24.4%), representing 1.3 million (95% CI, 1.1-1.5), had very complex/poor health. Overall, 61.5% (95% CI, 57.5%-65.3%), representing 3.8 million (95% CI, 3.4-4.2), had an HbA1c level of less than 7%; this proportion did not differ across health status categories (62.8% [95% CI, 56.9%-68.3%]) were relatively healthy, 63.0% (95% CI, 57.0%-68.6%) had complex/intermediate health, and 56.4% (95% CI, 49.7%-62.9%) had very complex/poor health (P = .26). Of the older adults with an HbA1c level of less than 7%, 54.9% (95% CI, 50.4%-59.3%) were treated with either insulin or sulfonylureas; this proportion was similar across health status categories (50.8% [95% CI, 45.1%-56.5%] were relatively healthy, 58.7% [95% CI, 49.4%-67.5%] had complex/intermediate health, and 60.0% [95% CI, 51.4%-68.1%] had very complex/poor health; P = .14). During the 10 study years, there were no significant changes in the proportion of older adults with an HbA1c level of less than 7% (P = .34), the proportion with an HbA1c level of less than 7% who had complex/intermediate or very complex/poor health (P = .27), or the proportion with an HbA1c level of less than 7% who were treated with insulin or sulfonylureas despite having complex/intermediate or very complex/poor health (P = .65). CONCLUSIONS AND RELEVANCE: Although the harms of intensive treatment likely exceed the benefits for older patients with complex/intermediate or very complex/poor health status, most of these adults reached tight glycemic targets between 2001 and 2010. Most of them were treated with insulin or sulfonylureas, which may lead to severe hypoglycemia. Our findings suggest that a substantial proportion of older adults with diabetes were potentially overtreated.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a nationally representative NHANES sample of older US adults with diabetes from 2001–2010, most had tight glycemic control (HbA1c <7%), including many with complex/intermediate or very complex/poor health. Many of these adults were treated with insulin or sulfonylureas, suggesting substantial potential overtreatment.
Key findings
- Among 1288 older adults with diabetes, 61.5% (95% CI, 57.5%–65.3%), representing 3.8 million US adults, had HbA1c <7%; this proportion did not differ significantly by health status: 62.8% relatively healthy, 63.0% complex/intermediate, and 56.4% very complex/poor (P = .26).
- Of those with HbA1c <7%, 54.9% (95% CI, 50.4%–59.3%) were treated with insulin or sulfonylureas; treatment was similar across health status categories: 50.8% relatively healthy, 58.7% complex/intermediate, and 60.0% very complex/poor (P = .14).
- Among adults with complex/intermediate or very complex/poor health, approximately 60% (or 1.0 million) with HbA1c <7% were treated with insulin or sulfonylureas.
- Over the 10 study years, there were no significant trends in the proportion with HbA1c <7% (P = .34), the proportion with HbA1c <7% who had complex/intermediate or very complex/poor health (P = .27), or treatment with insulin/sulfonylureas among those with complex/intermediate or very complex/poor health (P = .65).
Methods
- Cross-sectional analysis of NHANES data from 2001–2010, including 1288 adults aged ≥65 years with self-reported diabetes and an HbA1c measurement; analyses incorporated complex survey design to produce nationally representative estimates.
- Health status was classified using the ADA/AGS framework: very complex/poor health if dialysis-dependent or ≥2 ADL impairments; complex/intermediate health if ≥3 chronic conditions or ≥2 IADL impairments; relatively healthy if neither.
- Outcomes were tight glycemic control (HbA1c <7%; also examined <6.5%) and use of diabetes medications likely to cause hypoglycemia (insulin or sulfonylureas); weighted proportions and logistic regression were used to assess trends.
Limitations
- The paper states that combining NHANES cycles may have underpowered detection of subtle trends; medication use relied on prescriptions brought to examination, with some combination therapies not subcategorized; health status used limited ADL/IADL questions and did not account for dementia or cognitive impairment, possibly overestimating relatively healthy adults and underestimating overtreatment; NHANES excludes institutionalized adults; direct harm such as hypoglycemia could not be determined; HbA1c is a poor predictor of self-reported serious hypoglycemia; and a possible shift in HbA1c distribution toward higher values may underestimate overtreatment.
- Evident from the text: the cross-sectional design cannot establish causality between treatment and outcomes, and the study lacked data on active cancer, clinical depression, falls, and other ADL/IADL impairments used in the ADA/AGS framework.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 36 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 41.9% (95% CI, 37.9%–46.1%) of older adults had an HbA1c level of less than 6.5%”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, large proportions of participants with HbA1c levels of less than 6.5% were treated with insulin or sulfonylureas across health status categories (43.9% [95% CI, 36.8%–51.3%] of relatively healthy, 52.3% [95% CI, 40.4%–64.0%] with complex/intermediate health, and 56.3% [95% CI, 44.1%–67.8%] with very complex/poor health).”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“32.2% (95% CI, 28.7%–35.9%) had an HbA1c level of 7% to 8.9%”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most of them were treated with insulin or sulfonylureas, which may lead to severe hypoglycemia.”
- Also stated in: § Discussion · plain
“Moreover, approximately 60% (or 1.0 million) of adults with complex or very complex medical problems were treated with insulin or sulfonylureas to achieve tight glycemic targets, which may lead to severe hypoglycemia.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > CONCLUSIONS AND RELEVANCE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“28.1% (95% CI, 24.8%–31.5%), representing 1.7 million (95% CI, 1.4–2.0), had complex/intermediate health”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > RESULTS
Strength:plain· not yet calibratedn = 1,288Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the harms of intensive treatment likely exceed the benefits for older patients with complex/intermediate or very complex/poor health status, most of these adults reached tight glycemic targets between 2001 and 2010.”
- Also stated in: § Discussion · plain
“Despite unproven benefits and potential harms of tight glycemic control in older persons with extensive comorbidities, most older adults with complex/intermediate and very complex/poor health had an HbA1c level of less than 7%, corresponding to 1.8 million persons.”
- Also stated in: § Conclusions · plain
“Using a nationally representative sample of US adults, we showed that nearly two-thirds of older adults with diabetes who have complex/intermediate or very complex/poor health attained tight glycemic control.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > CONCLUSIONS AND RELEVANCE
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this proportion did not differ across health status categories (62.8% [95% CI, 56.9%–68.3%]) were relatively healthy, 63.0% (95% CI, 57.0%–68.6%) had complex/intermediate health, and 56.4% (95% CI, 49.7%–62.9%) had very complex/poor health (P = .26).”
- Also stated in: § Results · plain
“There were no significant differences in the proportions of patients who attained tight (HbA1c level, <7%), moderate (HbA1c level, 7%–8.9%), or poor (HbA1c level, ≥9%) glycemic control across health status categories (P = .43)”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, among participants with an HbA1c level of less than 7% who had complex/intermediate or very complex/poor health, treatment with insulin or sulfonylureas remained stable over time (P = .65)”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or the proportion with an HbA1c level of less than 7% who were treated with insulin or sulfonylureas despite having complex/intermediate or very complex/poor health (P = .65).”
- Also stated in: § Discussion · plain
“We did not find significant changes in treatment patterns across health status over time.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > RESULTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the older adults with an HbA1c level of less than 7%, 54.9% (95% CI, 50.4%–59.3%) were treated with either insulin or sulfonylureas”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 18
- It may state two separate claims as one. 14
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“21.2% (95% CI, 18.3%–24.4%), representing 1.3 million (95% CI, 1.1–1.5), had very complex/poor health.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > RESULTS
Strength:plain· not yet calibratedn = 1,288Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Current recommendations for diabetes management,2,11,12 including The 2012 ADA and American Geriatrics Society (AGS) consensus statement,13 endorse higher glycemic targets for older patients with multiple comorbidities, functional impairments, established diabetic complications, or limited life expectancy.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > CONCLUSIONS AND RELEVANCE
What the sources say
- Not checked yetcites [2] American Diabetes Association Standards of medical care in diabetes: 2014 Diabetes Care 2014 37 suppl 1 S14 S80 24357209
- Not checked yetcites [11] Management of Diabetes Mellitus Update Working Group VA/DoD clinical practice guideline: management of diabetes mellitus (2010). Version 4.0 Washington, DC Veterans Health Administration and Department of Defense 2010 http://www.healthquality.va.gov/guidelines/CD/diabetes/DM2010_SUM-v4.pdf Accessed November 26, 2014
- Not checked yetcites [12] Brown AF Mangione CM Saliba D Sarkisian CA California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes Guidelines for improving the care of the older person with diabetes mellitus J Am Geriatr Soc 2003 51 5 suppl guidelines S265 S280 12694461
- Not checked yetcites [13] Kirkman MS Briscoe VJ Clark N Diabetes in older adults Diabetes Care 2012 35 12 2650 2664 23100048 PMC3507610
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Glucose-lowering agents have been implicated in one-fourth of emergency hospitalizations for adverse drug events in older US adults, nearly all of them for hypoglycemia.9”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > CONCLUSIONS AND RELEVANCE
What the sources say
- Not checked yetcites [9] Budnitz DS Lovegrove MC Shehab N Richards CL Emergency hospitalizations for adverse drug events in older Americans N Engl J Med 2011 365 21 2002 2012 22111719
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We could not determine the presence of other indicators of very complex/poor health status per the ADA/AGS framework, including end-stage (stage III–IV) congestive heart failure, oxygen-dependent lung disease, uncontrolled metastatic cancer, or severe cognitive impairment.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Health Status
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All analyses incorporated complex survey design to produce nationally representative estimates.”
- Also stated in: § Statistical Analysis · plain
“All analyses incorporated a complex survey design using NHANES-recommended methods to produce nationally representative estimates.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > DESIGN, SETTING, AND PARTICIPANTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Also stated in: § Statistical Analysis · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We also did not include hypertension because it is highly prevalent and usually not considered a serious chronic illness.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Health Status
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“We classified older adults with diabetes into 3 health status categories endorsed by the ADA/AGS framework for considering treatment goals for glycemia.13”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Health Status
What the sources say
- Not checked yetcites [13] Kirkman MS Briscoe VJ Clark N Diabetes in older adults Diabetes Care 2012 35 12 2650 2664 23100048 PMC3507610
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Receipt and type of oral glucose-lowering treatment was based on review of medications brought in to the examination; insulin use was based on review of medications brought in or self-reported use of insulin, because participants may not always bring vials or pens to the examination.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Glucose-Lowering Treatment
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To preserve statistical power in these trend analyses, we combined participants with complex/intermediate and very complex/poor health status into 1 category.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Statistical Analysis
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“we did not have information on active cancer, clinical diagnosis of depression, or falls.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Health Status
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The NHANES uses stratified, multistage, probability-cluster techniques to ensure that sample populations are representative of the nation’s noninstitutionalized civilians.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Study Source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Laboratory method crossover studies were conducted at the time of each of the laboratory instrument changes.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Glycemic Control
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The reasons for higher glycemic targets in these persons are 2-fold: intensive glycemic control is unlikely to result in a benefit, but it is associated with a risk for harm.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Abstract > CONCLUSIONS AND RELEVANCE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Other ADLs and instrumental ADLs were not assessed in the NHANES.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Health Status
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This study was deemed exempt from further review by the University of California, San Francisco, Institutional Review Board because it used only deidentified secondary data.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Study Source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Both laboratories that analyzed NHANES HbA1c data from 2001–2010 were standardized by participating in the National Glycohemoglobin Standardization Program, and no adjustment across years for the HbA1c assay has been recommended.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Methods > Glycemic Control
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“Some combinations of comorbid conditions used to categorize health status may have stronger associations with hypoglycemia and life expectancy than others; however, to the extent possible, we have followed the ADA/AGS framework,13 which does not distinguish between these combinations.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Discussion
What the sources say
- Not checked yetcites [13] Kirkman MS Briscoe VJ Clark N Diabetes in older adults Diabetes Care 2012 35 12 2650 2664 23100048 PMC3507610
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“In addition, we incorporated functional impairments, which are an important risk factor for adverse outcomes in diabetes treatment but are not captured in administrative records such as those used in the study by Tseng et al.19”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Discussion
What the sources say
- Not checked yetcites [19] Tseng CL Soroka O Maney M Aron DC Pogach LM Assessing potential glycemic overtreatment in persons at hypoglycemic risk JAMA Intern Med 2014 174 2 259 268 24322626
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The ADA has only recently endorsed individualized glycemic targets, and it is possible that potential overtreatment may have declined since 2010; however, the Veteran Affairs and AGS guidelines have endorsed this approach for nearly a decade and we detected no signal to suggest a change.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Discussion
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We were not able to determine whether potential overtreatment directly resulted in harm, such as hypoglycemia.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We combined NHANES data from 2001 through 2010 to increase our sample size, but our study may have been underpowered to detect more subtle changes in treatment patterns over time.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Discussion
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These vulnerable adults are unlikely to experience the benefits of intensive glycemic control and instead are likely to experience harms from treatment, such as hypoglycemia and other adverse effects.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Conclusions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We used nationally representative samples (with equal numbers of men and women) served by different health systems that are more generalizable to the US population at large.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Given incomplete information on all comorbidities in our study, it is likely that we underestimated the complexity of health status, and thus, true estimates of adults who are potentially overtreated may be even higher.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Discussion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We categorized participants according to health status based on a limited number of questions about ADL and instrumental ADL impairments and did not take into account dementia or cognitive impairment; therefore, we may have overestimated the number of adults who were relatively healthy and underestimated potential overtreatment.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Discussion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Use of medications was based on prescriptions brought in for examination; a small percentage of medications were classified in NHANES as combination therapy and were not otherwise subcategorized, although some may have included sulfonylureas.”
§ Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control > Discussion
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it has been suggested that a tight glycemic control with a target A1C of 6.0% may not be ideal for older/frail individuals, those with longer duration of diabetes, advanced coronary artery disease (CAD) and a known history of severe hypoglycemia (32,33)”
From Targets for Glycemic Control (2018) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intensive glycemic management with medication plans including insulin and sulfonylureas in older adults with complex medical conditions has been identified as overtreatment and found to be very common in clinical practice (100-104)”
From 13. Older Adults: Standards of Care in Diabetes—2025 (2025) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intensive glycemic management in older adults, particularly those with complex health status, with medication plans that increase the risk of hypoglycemia through use of insulin and/or sulfonylureas has been identified as overtreatment, is common in clinical practice”
From 13. Older Adults: Standards of Care in Diabetes—2026 (2026) · cites this paper as [111]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Intensive glycemic management with medication plans including insulin and sulfonylureas in older adults with complex medical conditions has been identified as overtreatment and found to be very common in clinical practice (100-104)”
From 13. Older Adults: Standards of Care in Diabetes—2025 (2025) · cites this paper as [102]
In the citing paper
“Individuals with a long duration of diabetes, a known history of hypoglycemia, advanced atherosclerosis, or advanced age/frailty may benefit from less aggressive targets (67,68).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [67]
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,675
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Emergency hospitalizations for adverse drug events in older Americans.
Budnitz, D., Lovegrove, M., Shehab, N., & Richards, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1103053 · Cited by 1,748
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Kirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1801 · Cited by 1,274
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 408
Diabetes Distress and Quality of Life in Adults with Diabetes
Hoogendoorn, C. J., Shapira, A., Delgado, J. F. R., Kane, N. S., & Gonzalez, J. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-33286-0_20 · Cited by 11
Rowe, T. A., Brown, T., Doctor, J. N., Linder, J. A., & Persell, S. D. (2021) · BMC Family Practice · doi:10.1186/s12875-021-01440-w · Cited by 11
Reducing Care Overuse in Older Patients Using Professional Norms and Accountability
Persell, S. D., Petito, L. C., Lee, J. Y., Meeker, D., Doctor, J. N., Goldstein, N. J., Fox, C. R., Rowe, T. A., Linder, J. A., Chmiel, R., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2183 · Cited by 10
Finding the Sweet Spot: An Interactive Workshop on Diabetes Management in Older Adults
Triantafylidis, L. K., Phillips, S. C., Hawley, C. E., & Schwartz, A. W. (2019) · MedEdPORTAL · doi:10.15766/mep_2374-8265.10845 · Cited by 10
Ko, M. S. M., Lee, W. K., Ang, L. C., Goh, S., Bee, Y. M., & Teh, M. M. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109236 · Cited by 11
Optimizing management of glycaemia
Chatterjee, S., Khunti, K., & Davies, M. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.002 · Cited by 11
Tran, A. T., Berg, T. J., Mdala, I., Gjelsvik, B., Cooper, J. G., Sandberg, S., Claudi, T., & Jenum, A. K. (2020) · Diabetic Medicine · doi:10.1111/dme.14500 · Cited by 10
Drug prescribing during the last year of life in very old people with diabetes
Hamada, S., & Gulliford, M. C. (2016) · Age and Ageing · doi:10.1093/ageing/afw174 · Cited by 10
“Potential overtreatment of blood glucose and blood pressure in older people were recently reported in the USA [10, 11].”
BackgroundMata‐Cases, M., Mauricio, D., Real, J., Vlacho, B., Liébana, L. R., Molist‐Brunet, N., Cedenilla, M., & Franch‐Nadal, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175134 · Cited by 10
Kotecha, P., Smith, S. M., Donahoo, W. T., DeKosky, S. T., Bian, J., & Guo, J. S. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.41939 · Cited by 8
Lega, I. C., Kapur, A., Leung, F., & Zahedi, A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.01.009 · Cited by 9
Hâncu, N., Janež, A., Lalic, N. M., Παπάνας, Ν., Rahelić, D., Román, G., Serafinceanu, C., Tentolouris, N., Vuković, B., Ylli, A., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01037-7 · Cited by 9
“On the other hand, delayed deintensification of a therapeutic regimen can also be an important inertia factor, as overtreatment conveys a risk of further complications, especially in the elderly population [8].”
BackgroundOvertreatment and associated risk factors among multimorbid older patients with diabetes
Baretella, O., Alwan, H., Feller, M., Aubert, C. E., Giovane, C. D., Papazoglou, D. D., Christiaens, A., Meinders, A., Byrne, S., Kearney, P. M., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18465 · Cited by 9
“The level of overtreatment of T2DM in our study is comparable to recent studies also having documented a higher proportion of overtreatment than undertreatment.(7,9,10,15,16) A US study using Medicare data found that 11% of patients 65 years and older with T2DM were overtreated, and deintensification of overtreatment…”
BackgroundResultInfluentialAn update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzı́k, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 9
Westall, S., Narayanan, R. P., Watmough, S., Irving, G. J., Furlong, N. J., McNulty, S., Bujawansa, S., & Hardy, K. J. (2022) · Clinical Medicine · doi:10.7861/clinmed.2021-0764 · Cited by 12
Gungabissoon, U., Broadbent, M. T. M., Perera, G., Ashworth, M. J., Galwey, N. W., & Stewart, R. J. (2022) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2022.04.045 · Cited by 9
A Retrospective Time Trend Study Of Diabetes Overtreatment In Geriatric Patients
Wojszel, Z. B., & Kasiukiewicz, A. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s221179 · Cited by 9
“Despite clear guidelines recommending the higher glycemic targets in certain subgroups of older people, too tight glycemic control was noticed in some studies.(10,11) It concerned also a high proportion of patients admitted to our geriatric ward in 2009–2010.”
BackgroundRowe, T. A., Brown, T., Lee, J. Y., Linder, J. A., Friedberg, M. W., Doctor, J. N., Meeker, D., Ciolino, J. D., & Persell, S. D. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05748-8 · Cited by 9
Haymana, C., Sönmez, A., Demirci, İ., Yaylalı, G. F., Nuhoğlu, İ., Sancak, S., Yılmaz, M., Altuntaş, Y., Dınççağ, N., Sabuncu, T., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108556 · Cited by 9
Prescription medication use among patients with type 2 diabetes in the United States: 1999–2020
Li, S., Pan, S., Jiang, S., Shin, J., Liu, G. G., & Lyu, B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15619 · Cited by 11
“37 It is essential to recognize that antidiabetic medications account for only a fraction of the overall medication burden and non-cardiometabolic medications were also commonly used among people with type 2 diabetes.”
BackgroundParker, M. M., Lipska, K. J., Gilliam, L. K., Grant, R. W., Haider, S., Huang, E. S., Jain, R. K., Laiteerapong, N., Liu, J. Y., Moffet, H. H., et al. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19352 · Cited by 8
Self-citationPiątkiewicz, P., Buraczewska-Leszczyńska, B., Kuczerowski, R., Bernat-Karpińska, M., Rabijewski, M., & Kowrach, M. (2016) · Kardiologia Polska · doi:10.5603/kp.a2016.0043 · Cited by 9
“Most of these patients reached tight glycaemic targets regardless of their health status category, and the harm caused by intensive glucose lowering exceeds the benefits for elderly patients with a complex (intermediate) or very complex (poor) health status [16].”
BackgroundIndividualizing diabetes care in older persons with multimorbidity
Sloane, P. D., & Pandya, N. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.07.019 · Cited by 8
Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients
Weinrauch, L. A., Bayliss, G. P., Segal, A. R., Liu, J., Wisniewski, E., & D’Elia, J. A. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12776 · Cited by 7
Wilson, B. M., Tseng, C., Soroka, O., POGACH, L. M., & Aron, D. C. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2692-3 · Cited by 7
Loughlin, A. M., Qiao, Q., Nunes, A. P., Öhman, P., Ezzy, S. M., Yochum, L., Clifford, C. R., Gately, R. V., Dore, D. D., & Seeger, J. D. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13175 · Cited by 8
“Intensive treatment for glycaemic control in elderly patients and/or patients with RI may place them at higher risk of hypoglycaemia and its complications.(9) In January 2012, the US Food and Drug Administration approved, Bydureon, a once-weekly form of exenatide (EQW), for the treatment of T2DM.”
BackgroundKuppin, C. S., Troxel, A. B., Belli, H. M., Schwartz, J. L., Blecker, S., Blaum, C. S., Szerencsy, A. C., Testa, P. A., & Devin, M. (2019) · Studies in health technology and informatics · doi:10.3233/shti190407 · Cited by 8
McCoy, R. G., Lipska, K. J., Houten, H. K. V., & Shah, N. D. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001878 · Cited by 7
Self-citationPersonalized medicine and proper dosage
Trasta, A. (2018) · EMBO Reports · doi:10.15252/embr.201845957 · Cited by 8
“Glucose-lowering medications to treat diabetes have been blamed for up to 25% of emergency hospitalizations in the USA to treat hypoglycemia [3].”
BackgroundNauck, M. A., Araki, A., Hehnke, U., Plat, A. W., Clark, D., & Khunti, K. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13240 · Cited by 8
Optimizing drug therapy in frail patients with type 2 diabetes mellitus
Molist‐Brunet, N., Sevilla‐Sánchez, D., Juvanteny, E. P., González-Bueno, J., BONADA, N. S., Cruz-Grullón, M., & Espaulella‐Panicot, J. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01342-z · Cited by 8
Use of diabetes medications in traditional Medicare and Medicare Advantage
Landon, B. E., Zaslavsky, A. M., Souza, J., & Ayanian, J. Z. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88602 · Cited by 9
Schleiden, L. J., Klima, G. J., Rodriguez, K. L., Ersek, M. T., Robinson, J. E., Hickson, R. P., Smith, D., Cashy, J., Sileanu, F. E., & Thorpe, C. T. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01110-3 · Cited by 7
“These findings concur with previous studies in both VA and non-VA settings [18–20].”
Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin
DeCarlo, K., Wallia, A., Kang, R. H., Cooper, A., Cherupally, M., Harris, S. A., Aikman, C., Liss, D. T., Ackermann, R. T., & O’Brien, M. J. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-02792-3 · Cited by 7
“However, prior research has not described medication fills using the consensus framework that categorizes patients based on end-stage comorbid conditions, dementia, and/ or residence in long term care [11].”
BackgroundKooda, K. J., Bellolio, F., Dierkhising, R., & Tande, A. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab872 · Cited by 7
Diabetes Mellitus Treatment Deintensification
Raghavan, S., & Matlock, D. D. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.117.003706 · Cited by 8
Zhu, M., Cui, M., Nathan, A. G., Press, V. G., Wan, W., Miles, C., Ali, R. S., Pusinelli, M., Huisingh-Scheetz, M. J., & Huang, E. S. (2024) · Health Science Reports · doi:10.1002/hsr2.2208 · Cited by 6
Pickering, A. N., Richardson, S., Rogal, S. S., Thorpe, C. T., Brach, J. S., & Radomski, T. R. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19550 · Cited by 6
Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?
Giugliano, D., Maiorino, M. I., Bellastella, G., Petrizzo, M., Ceriello, A., Genovese, S., & Esposito, K. (2015) · Endocrine · doi:10.1007/s12020-015-0549-2 · Cited by 7
Understanding Diabetes Overtreatment in Older Adults: Are We at an Intersection?
Bilal, A. (2024) · Diabetes Care · doi:10.2337/dci24-0075 · Cited by 6
Improving drug prescription in elderly diabetic patients
Formiga, F., & Rodríguez‐Mañas, L. (2016) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2015.12.015 · Cited by 6
Orsi, E., Bonora, E., Solini, A., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Zerbini, G., Morano, S., Nicolucci, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010246 · Cited by 6
“0% irrespective of health status and type of treatment, with no change over the 10-year study period [29].”
BackgroundSex Differences in Factors Contributing to the Racial Disparity in Diabetes Risk
Carson, A. P., Long, D. L., Cherrington, A., Dutton, G. R., Howard, V. J., Brown, T. M., Howard, G., Safford, M. M., & Cushman, M. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2020.09.016 · Cited by 7
Callahan, K. E., Lenoir, K. M., Usoh, C. O., Williamson, J. D., Brown, L. Y., Moses, A. W., Hinely, M., Neuwirth, Z. E., & Pajewski, N. M. (2022) · Diabetes Spectrum · doi:10.2337/ds21-0068 · Cited by 7
Hypoglycemia in Diabetes: Challenges and Opportunities in Care
Kreider, K. E., Padilla, B. I., & Pereira, K. C. (2017) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.08.032 · Cited by 6
Tsabar, N., Press, Y., Rotman, J., Klein, B., Grossman, Y., Vainshtein‐Tal, M., & Eilat‐Tsanani, S. (2018) · BMC Health Services Research · doi:10.1186/s12913-017-2812-0 · Cited by 6
“Since a substantial proportion of older adults with diabetes is potentially overtreated [16], an intervention to reduce overtreatment could be benefitial.”
BackgroundRaghavan, S., Liu, W. G., Ho, P. M., Plomondon, M. E., Barón, A. E., Caplan, L., Maddox, K. E. J., Magid, D. J., Saxon, D. R., Voils, C. I., et al. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.01.010 · Cited by 6
Aron, D. C., Tseng, C., Soroka, O., & POGACH, L. M. (2018) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzy151 · Cited by 6
Az antihyperglykaemiás terápia deeszkalációja 2-es típusú diabetesben – amikor a kevesebb több
Jermendy, G. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31488 · Cited by 7
Gotfredsen, D. R., VINTHER, S. M., Petersen, T. S., Cortes, R., Jensen, T. B., Jimenez‐Solem, E., & Christensen, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60818-5 · Cited by 6
Formiga, F., Gómez‐Huelgas, R., & Rodríguez‐Mañas, L. (2015) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2015.04.002 · Cited by 11
Culley, C. M., Perera, S., Marcum, Z. A., Kane‐Gill, S. L., & Handler, S. M. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13648 · Cited by 6
“Although SSI is not recommended for routine treatment of diabetes mellitus in elderly adults because of the risk of hypoglycemia and lack of improvement in hyperglycemia management,(8,13,14) it was frequently associated with hypoglycemia alerts that the system detected and hypoglycemic events reported in the literatur…”
BackgroundMcCoy, R. G., & Lipska, K. J. (2016) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2016-110462 · Cited by 6
“Two cohorts of active primary care patients 70 years or older were identified in 2012: (1) A glycated haemoglobin (HbA1c) cohort of patients receiving glucose-lowering medications; and (2) A BP cohort of patients receiving BP-lowering medications.”
MethodSelf-citationKanazawa, K., Suzuki, S., Koga, S., & Kuwabara, K. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108239 · Cited by 4
Craig, S. G., Anderson, T. J., Stark, P., Wilson, C. B., Carter, G., McEvoy, C. T., Creighton, L., Henderson, E., Porter, S., Alhalaiqa, F., et al. (2025) · Nursing Reports · doi:10.3390/nursrep15060188 · Cited by 4
“In addition, many nursing home residents have diminished functional capacity, frailty, and varying degrees of cognitive impairment, which exacerbate the challenges of diabetes care [12].”
Mismatch between ADA and AGS recommendations for glycated hemoglobin targets for older adults
Taşçı, İ., Safer, U., Naharcı, M. İ., & Sönmez, A. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.01.003 · Cited by 5
Akın, S. (2019) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2019.311 · Cited by 4
“Over-treatment prevalence was considerable when compared to other studies (15-19).”
BackgroundResultNguyen, B., Deardorff, W. J., Shi, Y., Jing, B., Lee, A. K., & Lee, S. J. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17962 · Cited by 5
Self-citationDong, H., Wang, J., Hu, P. F., & Lu, N. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108516 · Cited by 5
Haider, S., Parker, M. M., Huang, E. S., Grant, R. W., Moffet, H. H., Laiteerapong, N., Jain, R. K., Liu, J. Y., Lipska, K. J., & Karter, A. J. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18870 · Cited by 5
“7,11 De-intensification requires both clinician and patient to engage in a shared decision-making process.”
BackgroundSelf-citationSangrós-González, F. J., Martínez-Candela, J., Lachica, L. Á., Díez‐Espino, J., Millaruelo-Trillo, J. M., Soidán, F. J. G., Fernández, L. C., & Loiola, P. E. (2017) · Revista Clínica Española · doi:10.1016/j.rce.2017.08.003 · Cited by 5
Management of older hospitalized patients with type 2 diabetes using linagliptin: Lina-Older study
Perez-Belmonte, L. M., Osuna‐Sánchez, J., Ricci, M., Millán‐Gómez, M., Lopez-Carmona, M. D., Barbancho, M. Á., Bernal-López, M. R., Jansen‐Chaparro, S., Lara, J. P., & Gómez‐Huelgas, R. (2022) · Panminerva Medica · doi:10.23736/s0031-0808.21.04085-4 · Cited by 5
Ma, H., Zhang, J., Meng, B., Wang, K., Li, Y., & Liang, N. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322886 · Cited by 5
Reducing hypoglycemia from overtreatment of type 2 diabetes in older adults: The HypoPrevent study
Koehn, D. A., Dungan, K. M., Wallia, A., Lucas, D. O., Lash, R. W., Becker, M. N., Dardick, L. D., & Boord, J. B. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18566 · Cited by 4
Integrating medical and surgical therapies to optimize the outcomes of type 2 diabetes
Ceccarini, G., Ciccarone, A. M., Santini, F., & Prato, S. D. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.01.035 · Cited by 4
What Do Clinical Supervisors Require to Teach Residents in Family Medicine How to Care for Seniors?
Giguere, A. M. C., Lebel, P., Morin, M., Proust, F., Rodríguez, C., Carnovale, V., Champagne, L., Légaré, F., Carmichael, P., Martineau, B., et al. (2018) · Canadian Journal on Aging / La Revue canadienne du vieillissement · doi:10.1017/s0714980817000460 · Cited by 4
“In this era of overdiagnosis and overtreatment, seniors are at even greater risk of adverse events from polypharmacy (Lipska et al., 2015).”
BackgroundGómez‐Huelgas, R., González, D., Abadías, M., Puig, J., & Ena, J. (2019) · Revista Clínica Española · doi:10.1016/j.rce.2019.05.011 · Cited by 5
Gómez‐Huelgas, R., González, D., Abadías, M., Puig, J., & Ena, J. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.05.007 · Cited by 4
Naser, A. Y., Alsairafi, Z. K., Alwafi, H. H., Turkistani, F. M., Bokhari, N. S., Alenazi, B., Dahmash, E. Z., & Alyami, H. S. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13662 · Cited by 4
Westall, S., Watmough, S., Narayanan, R. P., Irving, G. J., & Hardy, K. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275980 · Cited by 4
“Far from being a standardised approach, glycated haemoglobin targets are often individualised to the patient in response to the presence of established cardiovascular disease [1– 3], advanced age [4, 5], long diabetes duration [6], frailty [7, 8], excessive comorbidity [9], history of severe hypoglycaemia [10] and com…”
BackgroundGlycemic control and prescription profiles in internal medicine inpatients: The role of frailty
Arévalo‐Lorido, J. C., Carretero‐Gómez, J., Rodriguez, P. V., Gómez‐Huelgas, R., Silvente, C. M., Lora, F. J. S., Ares, E. I., Pelegrín, A. P. I., Hernández, O. P., & Ena, J. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.022 · Cited by 4
Weinrauch, L. A., Segal, A. R., Bayliss, G. P., Liu, J., Wisniewski, E., & D’Elia, J. A. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx020 · Cited by 4
“This study also does not address the frequency of overtreatment with resultant hypoglycemia [13] or the reasons for the use of medications deemed inappropriate for use as renal function declines [14].”
BackgroundDiabetes management in older people: a focus on cardiovascular risk reduction
McNicholas, E., & Abdelhafiz, A. H. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1246346 · Cited by 4
“This trend of inappropriate use of hypoglycemic medications has also been shown in other studies [68,69].”
ResultDiabetes treatment deintensification in nursing homes: When less is more
Lega, I. C., & Rochon, P. A. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17832 · Cited by 5
Ma, Y., Zhao, Y., Wei, R., Qiao, J., Luo, J., Zhang, L., Zhang, J., Deng, M., Yang, Y., Wang, W., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549244 · Cited by 3
“Despite current guidelines recommending a moderate glycemic target in older patients with multiple comorbidities, overtreatment of diabetes in elderly patients remains common (Lipska et al., 2015).”
RSSDI guidelines for management of type 2 diabetes mellitus in older adults
Jagadeesha, A., Viswanathan, V., Agarwal, S., Maheshwari, A., Virmani, A. K., Nagendra, L., Amarnath, A., Chawla, M. S., Jethwani, P., Parikh, R. M., et al. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01613-8 · Cited by 4
Belli, H. M., Troxel, A. B., Blecker, S., Anderman, J., Wong, C., Martinez, T. R., & Mann, D. M. (2021) · JMIR Research Protocols · doi:10.2196/28723 · Cited by 3
“Providers may be unaware of these guidelines, resulting in excessive glycemic indices in older adults [30].”
BackgroundTabué-Teguo, M., Simo, N., Rambhojan, C., Letchimy, L., Bonnet, M., Vélayoudom, F.-L., & Boucaud‐Maitre, D. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03008-5 · Cited by 3
Gudi, S. K., Bugden, S., Singer, A. G., & Falk, J. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.02.010 · Cited by 3
de Belen, E., Ganesan, D., Paculdo, D. R., Gill, R. D., & Peabody, J. W. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028634 · Cited by 3
Kutz, A., Kim, D. H., Liu, J., Munshi, M. N., & Patorno, E. (2025) · Diabetes Care · doi:10.2337/dc24-1795 · Cited by 3
Weise, S., Oelschläger, C., Unverzagt, S., Abendroth, J., Heise, M., & Frese, T. (2025) · European Journal of General Practice · doi:10.1080/13814788.2024.2447723 · Cited by 3
“…particularly for elderly patients with DM2 with a limited life expectancy, e.g. aged 80 years and above or those living in a nursing home [21,22]. this entails discussing treat-ment goals, benefits, risks, and patient preferences in a shared-decision making process [23]. however, elderly…”
Diabetes update: Your guide to the latest ADA standards.
Johnson, E. L., Warren, F., SKOLNIK, N., & Shubrook, J. H. (2016) · PubMed · Cited by 3
Деякі аспекти медикаментозної терапії цукрового діабету 2-го типу у людей з надмірною масою тіла
Jargin, S. V. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.5.2019.180046 · Cited by 3
Profile of diabetes in men aged 79–97 years: the Western Australian Health in Men Study
Henze, M. M., Alfonso, H. S., Flicker, L. A., GEORGE, J. D., Chubb, S. A. P., Hankey, G. J., Almeida, O. P., Golledge, J., Norman, P. E., & Yeap, B. B. (2016) · Diabetic Medicine · doi:10.1111/dme.13274 · Cited by 3
Kublin, O., & Stȩpień, M. (2019) · Clinical Diabetology · doi:10.5603/dk.2019.0006 · Cited by 3
Laiteerapong, N., Ham, S. A., Nathan, A. G., Sargis, R. M., Quinn, M. T., & Huang, E. S. (2019) · Medicine · doi:10.1097/md.0000000000018491 · Cited by 3
“0% is great, especially because achieving this level of HbA1c control often relies on the use of insulin or sulfonylureas, which confers a high risk for hypoglycemia.([11]) The vast majority of our physicians reported that they prioritized the same clinical variables (risk for hypoglycemia from treatment, history of d…”
BackgroundSinclair, A. J. (2021) · Age and Ageing · doi:10.1093/ageing/afab165 · Cited by 3
A CGM-Based model for predicting hypoglycemia in type 2 diabetes patients with TIR in target
Lu, J., Chen, D., Lin, B., Liu, Z., Yang, Y., He, L., Yan, J., Yang, D., & Xu, W. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01713-9 · Cited by 5
“However, intensive glycemic control strategies significantly increase the risk of hypoglycemia, posing a considerable obstacle to achieving optimal glycemic control in individuals with diabetes [26].”
Chaitoff, A. M., Weir, K. R., Marshall, V. D., & Vordenberg, S. E. (2025) · Health Expectations · doi:10.1111/hex.70366 · Cited by 2
Continuous glucose monitoring in high-risk individuals
Chen, Z., Zhang, Y., Sun, L., & Guo, W. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120733 · Cited by 2
Controlling glucose levels in elderly people—benefits versus risks
Riddle, M. C. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.23 · Cited by 2
“Leave Well Enough Alone”: A New Mantra for management of diabetes in the elderly
Ryan, P. M. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13301 · Cited by 2
Wallis, K. A., Wells, S. J., Selak, V., & Poppe, K. (2020) · Australian Journal of Primary Health · doi:10.1071/py19246 · Cited by 2
Glinkina, I. V., Владимировна, Б. А., Shyman, A. S., Oderiy, A. V., Khan, S. A., Евгеньевна, Р. Г., Моргунова, Т. Б., & Fadeev, V. V. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-56-67 · Cited by 2
Liu, W., Gao, Y., Zhang, R., Gong, S., Wang, X., Wang, Y., Cai, X., Zhang, X., Xie, X., Han, X., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03820-5 · Cited by 3
“Therefore, appropriate selection of an insulin regimen is essential to reduce the risk of adverse events, such as hypoglycemia and weight gain [12, 13].”
Nishtala, P. S., & Salahudeen, M. S. (2016) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098616660948 · Cited by 2
“5%), and may be appropriate in patients who are relatively healthy [Lipska et al. 2015].”
BackgroundMinimally Disruptive Diabetes Care for the Elderly
Spencer‐Bonilla, G., Rodríguez‐Gutiérrez, R., & Montori, V. M. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0380 · Cited by 2
“These well-intentioned statements, however, do not guide clinicians in enacting this patient-centered approach, and practice-based evidence suggests that they are not implemented.(15) Treatments that account for variability in routines and appetite usually demand more work and more decisions from patients, and may be…”
BackgroundMyers, A. K., Garnica, P., & Ling, J. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000667 · Cited by 4
POGACH, L. M., & Aron, D. C. (2018) · Israel Journal of Health Policy Research · doi:10.1186/s13584-018-0216-1 · Cited by 2
“About half of the US population 65–69 years of age fall into these categories [11].”
Background
Metadata
- Authors
- Lipska, K. J., Ross, J. S., Miao, Y., Shah, N. D., Lee, S. J., & Steinman, M. A.
- Affiliations
- Yale New Haven Hospital (US)
- San Francisco VA Medical Center (US)
- Mayo Clinic (US)
- Corresponding author
- Lipska, Kasia J.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2015-03-01
- Volume
- 175
- Issue
- 3
- Pages
- 356
- ISSN
- 2168-6106 (ISSN-L)
- PMC
- PMC4426991
- OpenAlex
- W1985992465
- Cited by
- 408
- References
- 34
- Citations by year
- 2026: 23 · 2025: 26 · 2024: 22 · 2023: 18 · 2022: 35 · 2021: 38 · 2020: 41 · 2019: 48 · 2018: 43 · 2017: 43 · 2016: 46 · 2015: 24
- FWCI
- 45.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000142)
- National Institute on Aging (K08AG032886, L30 AG045923, K23AG030999, K23AG048359, P30 AG21342, R03AG045086, T32AG019134, P30AG021342, P30AG044281)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- diabetes mellitus, older adults, overtreatment, tight glycemic control, HbA1c, hypoglycemia, insulin, sulfonylureas, comorbidities, functional limitations, activities of daily living, instrumental activities of daily living, health status, diabetes medication use, NHANES, cost-effectiveness, quality of life
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Blood Glucose, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Female, Health Status, Glycated Hemoglobin, Humans, Hypoglycemia, Iatrogenic Disease, Insulin, Male, Sulfonylurea Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
